Enanta Pharmaceuticals price target rises to $21.5 across 6 analysts
According to estimates from 6 analysts, the average price target for Enanta Pharmaceuticals shares rose from $21.29 to $21.5, with forecasts ranging from $17 to $32 per share. Using the November 20, 2026 close as a reference, the new target implies a potential upside of about 182%. The consensus rating from the 6 analysts remains "buy": 6 buy, 0 hold and 0 sell.
In 30 seconds
- The average price target from 6 analysts rises from $21.29 to $21.5 per share
- The forecast range runs from $17 to $32 per share
- The new target implies a potential upside of 182% versus the November 20, 2026 close
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.